Report cover image

Chagas disease - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 40 Pages
SKU # DEL18679358

Description

Chagas disease - Pipeline Insight, 2024



DelveInsight’s, “Chagas disease – Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chagas disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Chagas disease Understanding

Chagas disease: Overview

Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite Trypanosoma cruzi. About 6 million to 7 million people worldwide are estimated to be infected with T. cruzi, the parasite that causes Chagas Disease. The disease is found mainly in endemic areas of 21 continental Latin American countries, where it is mostly transmitted to humans and other mammals by contact with faeces or urine of triatomine bugs (vector-borne), known as 'kissing bugs', among many other popular names, depending on the geographical area. Chagas Disease presents itself in two phases. The initial acute phase lasts for about two months after infection. During the acute phase, a high number of parasites circulate in the blood but in most cases, symptoms are absent or mild and unspecific. During the chronic phase, the parasites are hidden mainly in the heart and digestive muscle. Up to 30% of patients suffer from cardiac disorders and up to 10% suffer from digestive (typically enlargement of the oesophagus or colon), neurological or mixed alterations. Chagas Disease can be treated with benznidazole and also nifurtimox.

""Chagas disease - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chagas disease pipeline landscape is provided which includes the disease overview and Chagas disease treatment guidelines. The assessment part of the report embraces, in depth Chagas disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chagas disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chagas disease R&D. The therapies under development are focused on novel approaches to treat/improve Chagas disease.

    • Chagas disease Emerging Drugs Chapters

    This segment of the Chagas disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

    Chagas disease Emerging Drugs
    • Fosravuconazole: Seren Pharmaceuticals
    Fosravuconazole is a new oral antifungal component developed by Eisai. In 2010, Eisai concluded a license agreement with Seren Pharma, granting them exclusive rights to develop, commercialize, and sublicense the agent in Japan. Fosravuconazole is a prodrug that improves the solubility and bioavailability of ravuconazole, the main active ingredient. When administered to humans, it is rapidly converted to ravuconazole. Ravuconazole demonstrates antifungal activity by inhibiting ergosterol biosynthesis, a membrane component of fungal cells. The drug is in Phase II stage of development for the treatmen of patients with Chagas Disease.

    Further product details are provided in the report……..

    Chagas disease: Therapeutic Assessment

    This segment of the report provides insights about the different Chagas disease drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Chagas disease
    There are approx. 5+ key companies which are developing the therapies for Chagas disease. The companies which have their Chagas disease drug candidates in the most advanced stage, i.e. Phase II include, Seren Pharmaceuticals.
    • Phases
    DelveInsight’s report covers around 5+ products under different phases of clinical development like
    • Late stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage product (Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates
    • Route of Administration
    Chagas disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Oral
    • Parenteral
    • Intravenous
    • Subcutaneous
    • Topical.
    • Molecule Type
    Products have been categorized under various Molecule types such as
    • Monoclonal Antibody
    • Peptides
    • Polymer
    • Small molecule
    • Gene therapy
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Chagas disease: Pipeline Development Activities

    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chagas disease therapeutic drugs key players involved in developing key drugs.

    Pipeline Development Activities

    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chagas disease drugs.

    Chagas disease Report Insights
    • Chagas disease Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs
    Chagas disease Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs
    Key Questions

    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Chagas disease drugs?
    • How many Chagas disease drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chagas disease?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chagas disease therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Chagas disease and their status?
    • What are the key designations that have been granted to the emerging drugs?

Table of Contents

40 Pages
Introduction
Executive Summary
Chagas disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Mid Stage Products (Phase II)
Comparative Analysis
Fosravuconazole: Seren Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical Stage Products
Comparative Analysis
SLV213: Selva therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chagas disease Key Companies
Chagas disease Key Products
Chagas disease- Unmet Needs
Chagas disease- Market Drivers and Barriers
Chagas disease- Future Perspectives and Conclusion
Chagas disease Analyst Views
Chagas disease Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us